Long-Term Antitumor Activity and Safety of Enzalutamide Monotherapy in Hormone Naïve Prostate Cancer: 3-Year Open Label Followup Results-Reference-Cited by-同舟云学术

Long-Term Antitumor Activity and Safety of Enzalutamide Monotherapy in Hormone Naïve Prostate Cancer: 3-Year Open Label Followup Results

Published:2018-02 Issue:2 Volume:199 Page:459-464
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Tombal Bertrand¹,Borre Michael²,Rathenborg Per³,Werbrouck Patrick⁴,Van Poppel Hendrik⁵,Heidenreich Axel⁶,Iversen Peter⁷,Braeckman Johan⁸,Heracek Jiri⁹,Baron Benoit¹⁰,Krivoshik Andrew¹¹,Hirmand Mohammad¹²,Smith Matthew R.¹³

Affiliation:

1. Cliniques universitaires Saint-Luc, Brussels, Belgium

2. Aarhus University Hospital, Aarhus, Denmark

3. Herlev Hospital, Herlev, Denmark

4. AZ Groeninge Kortrijk, Kortrijk, Belgium

5. Universitair ziekenhuis Leuven, Leuven, Belgium

6. Cologne University, Cologne, Germany

7. Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

8. Universitair ziekenhuis Brussels, Brussels, Belgium

9. Univerzita Karlova v Praze, Prague, Czech Republic

10. Astellas Pharma, Inc., Leiden, The Netherlands

11. Astellas Pharma, Inc., Northbrook, Illinois

12. Medivation, Inc., San Francisco, California

13. Massachusetts General Hospital Cancer Center, Boston, Massachusetts

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference23 articles.

1. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer;Taylor;Cancer,2009

2. Androgen deprivation therapy in the treatment of advanced prostate cancer;Perlmutter;Rev Urol,2007

3. Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand;Wang;BMC Cancer,2015

4. Quantifying the evidence for the risk of metabolic syndrome and its components following androgen deprivation therapy for prostate cancer: a meta-analysis;Bosco;PLoS One,2015

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Short-term Darolutamide (ODM-201) Concomitant to Radiation Therapy for Patients with Unfavorable Intermediate-risk Prostate Cancer: The Darius (AFU-GETUG P15) Phase 2 Trial Protocol;European Urology Oncology;2024-05

2. Role of enzalutamide in primary and recurrent non-metastatic hormone sensitive prostate cancer: a systematic review of prospective clinical trials;Prostate Cancer and Prostatic Diseases;2024-04-08

3. Hormone Therapy for Advanced Prostate Cancer;Prostate Cancer;2024

4. A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532);European Urology Oncology;2024-01

5. Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer;New England Journal of Medicine;2023-10-19